Evaluation of remission induction with hyper CVAD chemotherapy in ALL patients in seyedoshohada hospital in Isfehan in 1388 and 1389.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806142417N1

Enrollment

Registered

2010-12-30

Start date

2010-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukaemia. Acute lymphoblastic leukaemia

Interventions

Initial regimen: cyclophosphamide 300mg/m2 continuous infusion intravenously over 2 hours every 12 hours days 1 to 3 2- Vincristine 2mg IV days 4 to 11 3 - adriamycin 50mg/m2 intravenous injections o

Treatment - Drugs

Initial regimen: cyclophosphamide 300mg/m2 continuous infusion intravenously over 2 hours every 12 hours days 1 to 3 2- Vincristine 2mg IV days 4 to 11 3 - adriamycin 50mg/m2 intravenous injections

Eligibility

Sex/Gender

All

Age

14 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of ALL Exclusion criteria: age between 14-50, serum bilirubin less than 4mg/dl, cardiac output less than 50%, Pregnancy, performance status based on Karnophski scale less than 60

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Complete remission. Timepoint: At the end of treatment. Method of measurement: bone marrow examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Saleh Azadbakht

Isfahanl University of Medical Sciences

azadbakht.saleh@yahoo.com+98 31 1627 6140

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026